Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/3/2025 | Speculative Buy → Hold | The Benchmark Company | |
| 12/12/2024 | $8.00 | Buy | Maxim Group |
| 8/20/2021 | $4.00 | Speculative Buy | Benchmark |
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Ms Ann Cunningham to its Board of Directors as an independent Non-Executive Director, effective 17th April 2026. Ms Cunningham's appointment further strengthens Alterity's Board composition, adding significant global commercial and strategic expertise as the Company transitions toward late-stage development in Multiple System Atrophy (MSA). Ms Cunningham brings more than 25 years of global pharmac
MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will deliver an oral presentation during a Late Breaking Session at the American Academy of Neurology (AAN) Annual Meeting taking place April 18-22, 2026 in Chicago, IL, USA. Session: Late-breaking Science 2Type:Oral PresentationTitle:ATH434 Demonstrates Disease-Modifying Signal in
MELBOURNE, Australia and SAN FRANCISCO, April 15, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event featuring Roy Freeman, MD (Harvard Medical School, Beth Israel Deaconess Medical Center) and Daniel Claassen, MD, MS (Vanderbilt University Medical Center), alongside David Stamler, MD, (CEO, Alterity Therapeutics), to discuss the significant unmet need and current treatment landscape in Multiple System Atrophy (MSA), a rare, rapidly progressive neurodegenera
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold
Maxim Group initiated coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $8.00
Benchmark initiated coverage of Alterity Therapeutics with a rating of Speculative Buy and set a new price target of $4.00
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Ms Ann Cunningham to its Board of Directors as an independent Non-Executive Director, effective 17th April 2026. Ms Cunningham's appointment further strengthens Alterity's Board composition, adding significant global commercial and strategic expertise as the Company transitions toward late-stage development in Multiple System Atrophy (MSA). Ms Cunningham brings more than 25 years of global pharmac
MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov
− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme
SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)
SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)
SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)
3 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
3 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
3 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)